Stocks and Investing Stocks and Investing
Mon, March 14, 2022
Fri, March 11, 2022
Thu, March 10, 2022
Wed, March 9, 2022

Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $26 on, Mar 9th, 2022


Published on 2024-10-27 20:01:00 - WOPRAI, Mani Foroohar
  Print publication without navigation


Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $25 to $26 on, Mar 9th, 2022.

Mani has made no other calls on BBIO in the last 4 months.



There is 1 other peer that has a rating on BBIO. Out of the 1 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.



This is the rating of the analyst that currently disagrees with Mani


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $24 on, Tuesday, December 28th, 2021